Prostate cancer drug combination adds toxicity without clear benefit for tumors lacking targetable mutations
The prospective, multicenter, randomized phase 2 ZZ-FIRST clinical trial, led by the Vall d'Hebron Institute of Oncology's (VHIO) Prostate Cancer Group, evaluated the androgen receptor pathway inhibitor (ARPI) enzalutamide plus the poly(ADP-ribose) polymerase inhibitor (PARPi) talazoparib versus enz
<p>The prospective, multicenter, randomized phase 2 ZZ-FIRST clinical trial, led by the Vall d'Hebron Institute of Oncology's (VHIO) Prostate Cancer Group, evaluated the androgen receptor pathway inhibitor (ARPI) enzalutamide plus the poly(ADP-ribose) polymerase inhibitor (PARPi) talazoparib versus enz</p>